Ticker

Nkarta (NASDAQ: NKTX - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk. Profitability This table compares Nkarta and Bolt Biotherapeutics'

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March:

Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totaling 352 shares, a decrease of 83.8% from the December 15th total of 2,177 shares. Approximately 0.0% of the shares of the company are sold short. Based

Acumen Pharmaceuticals (NASDAQ: ABOS - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation. Earnings and Valuation This table compares Acumen